Case Report of a Patient with Advanced and Disseminated Gastric Carcinoma Treated by S-1

Česká verze

Authors: J. Katolická ¹; S. Rotnáglová ¹; J. Vaníček ²
Authors place of work: Onkologicko‑chirurgické oddělení, FN u sv. Anny v Brně ¹; Klinika zobrazovacích metod LF MU a FN u sv. Anny v Brně ²
Published in the journal: Klin Onkol 2014; 27(3): 207-209
Category: Kazuistika

Summary

Background:
Prognosis of patients with metastatic gastric cancer is abysmal, usually just a few months. S-1 is a peroral fluoropyrimidine antitumor drug. It is a fixed combination of three effective drugs –⁠ tegafur, gimeracil and oteracil potassium.

Case:
This is a case report of a 71-year-old man treated for local advanced and metastatic gastric carcinoma treated with combination of S-1 and cisplatin as a first line of therapy. Treatment response reached partial remission and lasted for six months. Treatment was very well tolerated, with no grade 3 and 4 toxicity. After progression, the patient was treated with further lines of therapy.

Conclusion:
In the Czech Republic, experience with S-1 drug is very limited. Our case report showed a good treatment response and minimal toxicity of this treatment, in concordance with results of the study FLAGS.

Key words:
case report –⁠ metastatic gastric cancer –⁠ chemotherapy –⁠ S ‑⁠ 1 –⁠ cisplatin

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
12. 2. 2014

Accepted:
5. 5. 2014

Zdroje

1. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/ S ‑⁠ 1 with cisplatin/ infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28(9): 1547 –⁠ 1553. doi: 10.1200/ JCO.2009.25.4706.

2. Tomášek J. Karcinom žaludku. Acta Medicinae 2012; 1(2): 49 –⁠ 51.

3. Price TJ, Shapiro JD, Segelov E et al. Management of advanced gastric cancer. Expert Rev Gastroenterol Hepatol 2012; 6(2): 199 –⁠ 208. doi: 10.1586/ egh.11.103.

4. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase IIIstudy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first‑line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24(31): 4991 –⁠ 4997.

5. Taiho. Comparison of results in subpopulations. Marketing Authorisation Application: S ‑⁠ 1.2009.

6. Nccn.org [homepage on the Internet]. National Comprehensive Cancer Network. Washington: c2014. Available from: www.nccn.org.

7. Vyzula R et al (eds). Modrá kniha České onkologické společnosti, 18. vyd. Brno: Masarykův onkologický ústav 2014. Dostupné z: http:/ / www.linkos.cz/ informace ‑⁠ pro‑praxi/ modra ‑⁠ kniha/ .

8. Waddell T, Verheij M, Allum W et al. Gastric cancer: ESMO ‑⁠ ESSO ‑⁠ ESTRO Clinical practice guidelines for diagnosis, treatment and follow‑up. Ann Oncol 2013; 24(6): 57 –⁠ 63.